Format

Send to

Choose Destination
Stem Cell Rev Rep. 2020 Feb 22. doi: 10.1007/s12015-020-09960-1. [Epub ahead of print]

Infusion of Mesenchymal Stem Cells to Treat Graft Versus Host Disease: the Role of HLA-G and the Impact of its Polymorphisms.

Author information

1
Immunogenetics and Histocompatibility Laboratory, Department of Genetics, Federal University of Paraná (UFPR), Curitiba, Brazil.
2
Core for Cell Technology, School of Medicine, Pontifical Catholic University of Paraná (PUCPR), Rua Imaculada Conceição, 1155, Curitiba, PR, 80215-901, Brazil.
3
Core for Cell Technology, School of Medicine, Pontifical Catholic University of Paraná (PUCPR), Rua Imaculada Conceição, 1155, Curitiba, PR, 80215-901, Brazil. alexandra.senegaglia@pucpr.br.

Abstract

Hematopoietic stem-cell transplantation is widely performed for the treatment of hematologic diseases and is increasingly being used for the experimental treatment of various autoimmune diseases. Despite the rapid evolution of this therapy, the mortality rate of patients undergoing this procedure is still high, mainly due to the development of graft versus host disease (GvHD). Even with the administration of immunosuppressive therapy, some patients manifest the chronic form of the disease. For these cases, infusion of mesenchymal stem cells (MSCs) was proposed as a therapeutic strategy, considering the immunosuppressive potential of these cells. This review describes the main results obtained in cell therapy with MSCs for the treatment of GvHD. Despite the encouraging results found, some points differed among the studies. Although the factors that influence the different results are uncertain, some investigators have suggested that variations in immunosuppressive molecules are responsible for these divergences. We highlight the key role of the HLA-G gene in modulating the immune response, and the importance of the polymorphisms and alleles of this gene associated with the outcome of the transplants. We suggest that the HLA-G gene and its polymorphisms be analyzed as a factor in selecting the MSCs to be used in treating GvHD, given its strong immunosuppressive role.

KEYWORDS:

Cell therapy; HLA-G polymorphism; Hematopoietic stem cell transplantation; Immunomodulation; human leukocyte antigen G gene

PMID:
32088839
DOI:
10.1007/s12015-020-09960-1

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center